Futura Medical PLC Investor Presentation on MED2002 (9991J)

TIDMFUM

RNS Number : 9991J

Futura Medical PLC

04 July 2017

 
 For immediate release   4 July 2017

Futura Medical plc

("Futura" or the "Company")

Investor Presentation on MED2002

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, is pleased to announce that the Company is today presenting to institutional investors on its topical gel for erectile dysfunction, MED2002.

MED2002 represents a breakthrough treatment for erectile dysfunction ("ED") with the potential to offer the fastest speed of onset, the least side-effects and the fewest contra-indications of any ED medication.

Today's presentation is based on the presentation that Futura gives to potential licensing partners and comprises a detailed insight into key aspects of the clinical development and commercial potential of the product.

The presentation is taking place at noon today at the Surrey Research Park, where Futura is based, as part of a capital markets event organised by N+1 Singer, the Company's nominated adviser and broker.

A copy of the slide deck accompanying the presentation is now available at the investor section of Futura's website, www.futuramedical.com.

No new price sensitive information will be disclosed.

For any further information please contact:

 
 Futura Medical plc 
 James Barder, Chief Executive                  Tel: +44 (0)1483 685 
                                                                 670 
 mail to: james.barder@futuramedical.com       www.futuramedical.com 
 
 N+1 Singer (Nominated Adviser 
  and Broker) 
 Aubrey Powell / Liz Yong                   Tel:+44 (0) 20 7496 3000 
 
 For media enquiries please 
  contact: 
 Buchanan 
 Mark Court / Sophie Cowles                 Tel: +44 (0)20 7466 5000 
  / Stephanie Watson

Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCRJMLTMBBMBLR

(END) Dow Jones Newswires

July 04, 2017 02:00 ET (06:00 GMT)

Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024